New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
People with college education, gay and bisexual men, and people who struggle to make clinic visits were more likely to prefer the long-acting option.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Advocates say the move is more politics than science.
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
Providers, payers, and health systems need to catch up, said Melanie Thompson, M.D., at the ACTHIV conference.
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.